The possibility of using Mexidol in neuropediatrics

Authors:
N.N. Zavadenko, N.Yu. Suvorinova, A.N. Zavadenko

FGAOU in Russian National Research Medical University named after N.I. Pirogov »Ministry of Health of Russia, Moscow, Russia

Place of publication:
a journal of neurology and psychiatry named after S.S. Korsakova, 2023, T. 123, No. 9, Issue. 2

Summary:
Mexol (ethylmethylhydroxypyridine succinate) is a modern neurometabolic drug that is increasingly used in neuropediatrics. The results of recent studies are considered, confirming the positive effects of pharmacotherapy with Mexidol in children with attention deficiency and hyperactivity disorder (ADHD), perinal lesions of the central nervous system (hypoxic-ischemic encephalopathy) and their consequences, neurological disorders and the delay in neuropsychic development after surgical interventions with congenital vices in congenital vices hearts, neuroinfections (meningitis, encephalitis), post -traumatic epilepsy. Given the unique multimodal action of Mexidol, it seems promising to expand the circle of indications for its use in neuropediatry, based on the results of new clinical studies, which will be organized in accordance with the modern principles of evidence -based medicine.

Keywords: Mexol (ethylmethylhydroxypyridine succinate), children, treatment, hypoxic and ischemic encephalopathy, attention deficiency syndrome, retention of neuropsychiatric development, meningitis, encephalitis, post-traumatic epilepsy.